Initial vaccination and revaccination with Type I PRRS 94881 MLV reduces viral load and infection with porcine reproductive and respiratory syndrome virus

Table 2 Percentage of gilts who were seropositive for PRRSV based on ELISA

Day	Group	% seropositive (95% CI)	P-value (vs challenge control)	P-value (vs revaccination)
0	Challenge control	0	–	–
	Revaccination	0	–	–
	Single vaccination	0	–	–
14	Challenge control	0 (0.0, 20.6)	N/A
	Revaccination	25 (7.3, 52.4)	0.101	N/A
	Single vaccination	0 (0.0, 20.6)	ND	0.101
21	Challenge control	0 (0.0, 20.6)	N/A
	Revaccination	56 (29.9, 80.2)	0.0008	N/A
	Single vaccination	0 (0.0, 20.6)	ND	0.0008
56	Challenge control	0 (0.0, 20.6)	N/A
	Revaccination	69 (41.3, 89.0)	0.0001	N/A
	Single vaccination	0 (0.0, 20.6)	ND	0.0001
70	Challenge control	0 (0.0, 20.6)	N/A
	Revaccination	69 (41.3, 89.0)	0.0001	N/A
	Single vaccination	69 (41.3, 89.0)	0.0001	1.0000
77	Challenge control	0 (0.0, 20.6)	N/A
	Revaccination	69 (41.3, 89.0)	0.0001	N/A
	Single vaccination	94 (69.8, 99.8)	< 0.0001	0.172
91	Challenge control	0 (0.0, 20.6)	N/A
	Revaccination	56 (29.9, 80.2)	0.0008	N/A
	Single vaccination	94 (69.8, 99.8)	< 0.0001	0.0373

Challenge control group (n = 16); Revaccination group (n = 16); Single-vaccination group (n = 16)
PRRS serology was assessed using ELISA
CI confidence interval, ELISA enzyme-linked immunosorbent assay, N/A not applicable, ND not determined, PRRSV Porcine reproductive and respiratory syndrome virus

ISSN: 2055-5660